PC-9 Cells

The PC-9 cell line is derived from a human lung adenocarcinoma, a subtype of non-small cell lung cancer (NSCLC). This cell line is particularly notable for harboring an activating mutation in the EGFR gene, specifically the exon 19 deletion (E746_A750del), which is a common driver mutation in NSCLC. This alteration makes PC-9 an invaluable model for studying the biology of EGFR-driven cancers and evaluating the efficacy of tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib, which specifically target this pathway. PC-9 cells have been extensively used in research focused on resistance mechanisms to EGFR TKIs, particularly the emergence of secondary mutations like T790M. These studies have informed the development of third-generation inhibitors such as osimertinib, which target both the primary EGFR mutation and resistance-associated alterations. The cell line also exhibits sensitivity to other inhibitors targeting downstream signaling pathways, including those involved in PI3K/AKT and MAPK signaling cascades, underscoring its utility in translational cancer research. In addition to its genetic and pharmacological attributes, PC-9 has been incorporated into high-throughput drug screening programs, facilitating the identification of compounds with selective activity against EGFR-mutated NSCLC. The line's well-characterized genomic landscape and consistent phenotypic behavior in vitro make it a cornerstone for both basic and applied lung cancer research, particularly in the context of targeted and combination therapy.